BIOMAT Database Logo BIOMAT Database Logo

Treatment of autonomic neuropathy with a somatostatin analogue SMS-201-995. 1986

R D Hoeldtke, and T M O'Dorisio, and G Boden

Eight patients with postprandial hypotension and orthostatic hypotension were treated with the somatostatin analogue SMS-201-995. Low doses of this drug (0.2-0.4 microgram/kg) raised the blood pressure after breakfast in all six patients with postprandial hypotension. 60 min after breakfast the mean sitting blood pressure was 35 +/- 10 (SEM) mm Hg higher after administration of SMS-201-995 0.4 microgram/kg than after placebo (p less than 0.001). Larger doses (up to 1.6 micrograms/kg) raised upright blood pressure during the postprandial period in five of seven patients. Before therapy three patients were unable to stand after eating; after an injection of SMS-201-995 0.8 microgram/kg at the beginning of breakfast they were able to walk for 35-100 min. The duration of therapeutic effect of each injection was 3-6 h. Treatment was followed by abdominal cramps and nausea in two patients with gastroparesis diabeticorum. SMS-201-995 holds promise as a treatment for postprandial hypotension and orthostatic hypotension.

UI MeSH Term Description Entries
D007022 Hypotension Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients. Blood Pressure, Low,Hypotension, Vascular,Low Blood Pressure,Vascular Hypotension
D007024 Hypotension, Orthostatic A significant drop in BLOOD PRESSURE after assuming a standing position. Orthostatic hypotension is a finding, and defined as a 20-mm Hg decrease in systolic pressure or a 10-mm Hg decrease in diastolic pressure 3 minutes after the person has risen from supine to standing. Symptoms generally include DIZZINESS, blurred vision, and SYNCOPE. Hypotension, Postural,Orthostatic Hypotension,Postural Hypotension
D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Amuno,Indocid,Indocin,Indomet 140,Indometacin,Indomethacin Hydrochloride,Metindol,Osmosin
D007329 Insulin Antagonists Compounds which inhibit or antagonize the biosynthesis or action of insulin. Antagonists, Insulin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002110 Caffeine A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine's most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes SMOOTH MUSCLE, stimulates CARDIAC MUSCLE, stimulates DIURESIS, and appears to be useful in the treatment of some types of headache. Several cellular actions of caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide PHOSPHODIESTERASES, antagonism of ADENOSINE RECEPTORS, and modulation of intracellular calcium handling. 1,3,7-Trimethylxanthine,Caffedrine,Coffeinum N,Coffeinum Purrum,Dexitac,Durvitan,No Doz,Percoffedrinol N,Percutaféine,Quick-Pep,Vivarin,Quick Pep,QuickPep
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005260 Female Females

Related Publications

R D Hoeldtke, and T M O'Dorisio, and G Boden
[Somatostatin analogue (SMS 201-995)].
February 1989, Harefuah,
R D Hoeldtke, and T M O'Dorisio, and G Boden
[Gastrointestinal fistulas. Treatment with a somatostatin analogue (SMS 201-995)].
January 1994, G.E.N,
R D Hoeldtke, and T M O'Dorisio, and G Boden
Effects of somatostatin analogue SMS 201-995.
June 1990, The British journal of surgery,
R D Hoeldtke, and T M O'Dorisio, and G Boden
Treatment of pancreatic fistula with the somatostatin analogue SMS 201-995.
July 1988, The British journal of surgery,
R D Hoeldtke, and T M O'Dorisio, and G Boden
Treatment of acromegaly with long acting somatostatin analogue SMS 201-995.
October 1988, Endocrinologia japonica,
R D Hoeldtke, and T M O'Dorisio, and G Boden
Treatment of severe reactive hypoglycemia with a somatostatin analogue (SMS 201-995).
November 1990, Archives of internal medicine,
R D Hoeldtke, and T M O'Dorisio, and G Boden
Paraneoplastic hypoglycaemia treated with somatostatin analogue SMS 201-995.
October 1996, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,
R D Hoeldtke, and T M O'Dorisio, and G Boden
Somatostatin analogue (SMS 201-995) in patients with gastrinomas.
November 1988, Surgery,
R D Hoeldtke, and T M O'Dorisio, and G Boden
Regression of metastatic vipoma with somatostatin analogue SMS 201-995.
April 1985, Lancet (London, England),
R D Hoeldtke, and T M O'Dorisio, and G Boden
Treatment of the dumping syndrome with the somatostatin analogue SMS 201-995.
February 1988, Annals of surgery,
Copied contents to your clipboard!